[go: up one dir, main page]

PE20230495A1 - Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer - Google Patents

Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Info

Publication number
PE20230495A1
PE20230495A1 PE2022002801A PE2022002801A PE20230495A1 PE 20230495 A1 PE20230495 A1 PE 20230495A1 PE 2022002801 A PE2022002801 A PE 2022002801A PE 2022002801 A PE2022002801 A PE 2022002801A PE 20230495 A1 PE20230495 A1 PE 20230495A1
Authority
PE
Peru
Prior art keywords
alpha
domain
cancer
vaccination
mica
Prior art date
Application number
PE2022002801A
Other languages
English (en)
Inventor
Kai Wucherpfennig
Soumya Badrinath
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of PE20230495A1 publication Critical patent/PE20230495A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001139—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion proporciona composiciones y metodos para tratar cancer en un sujeto al provocar una respuesta inmune contra un polipeptido del dominio alfa 3 de MIC
PE2022002801A 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer PE20230495A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263377P 2015-12-04 2015-12-04
US201662422454P 2016-11-15 2016-11-15
PCT/US2016/064969 WO2017096374A1 (en) 2015-12-04 2016-12-05 Vaccination with mica/b alpha 3 domain for the treatment of cancer

Publications (1)

Publication Number Publication Date
PE20230495A1 true PE20230495A1 (es) 2023-03-23

Family

ID=57590885

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022002801A PE20230495A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer
PE2018001072A PE20181158A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2018001072A PE20181158A1 (es) 2015-12-04 2016-12-05 Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer

Country Status (24)

Country Link
US (3) US10993971B2 (es)
EP (1) EP3383426A1 (es)
JP (3) JP7099956B2 (es)
KR (1) KR20180088458A (es)
CN (1) CN108770343A (es)
AU (2) AU2016362597C1 (es)
BR (1) BR112018010705A8 (es)
CA (1) CA3005910A1 (es)
CL (3) CL2018001470A1 (es)
CO (1) CO2018006642A2 (es)
CR (2) CR20230116A (es)
CU (2) CU24609B1 (es)
EA (1) EA201891287A1 (es)
IL (1) IL259490A (es)
MX (2) MX2018006785A (es)
MY (1) MY199248A (es)
NZ (1) NZ742663A (es)
PE (2) PE20230495A1 (es)
PH (1) PH12018501170A1 (es)
RU (2) RU2747296C2 (es)
SG (1) SG11201804597TA (es)
TN (1) TN2018000187A1 (es)
WO (1) WO2017096374A1 (es)
ZA (1) ZA202204223B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512564A (zh) * 2018-04-03 2021-03-16 赛诺菲 铁蛋白蛋白
CA3095174A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic ospa polypeptides
WO2019195291A1 (en) 2018-04-03 2019-10-10 Sanofi Antigenic respiratory syncytial virus polypeptides
EP3773708A2 (en) 2018-04-03 2021-02-17 Sanofi Antigenic epstein barr virus polypeptides
AU2021305084A1 (en) 2020-07-07 2023-02-02 Cancure, Llc MIC antibodies and binding agents and methods of using the same
CN116396398B (zh) * 2023-01-16 2024-07-16 四川大学 一种实现铁蛋白纳米颗粒可控自组装的方法以及基于该方法搭建的纳米颗粒抗原展示平台
WO2024222886A1 (zh) * 2023-04-28 2024-10-31 北京先声祥瑞生物制品股份有限公司 一种针对MICA/B靶点的mRNA肿瘤疫苗

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
IL98715A0 (en) 1990-08-13 1992-07-15 American Cyanamid Co Filamentous hemaglutinin of bodetella pertussis as a carrier molecule for conjugate vaccines
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
CA2135052A1 (en) 1992-05-06 1993-11-11 R. John Collier Diphtheria toxin receptor-binding region
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
ES2277362T5 (es) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
MY125387A (en) 1999-03-19 2006-07-31 Smithkline Beecham Biologicals S A Vaccine
AU781027B2 (en) 1999-04-09 2005-04-28 Department Of Health & Human Services Recombinant toxin a protein carrier for polysaccharide conjugate vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2002091998A2 (en) 2001-05-11 2002-11-21 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
ATE396739T1 (de) 2001-10-01 2008-06-15 Us Health Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
US6706305B2 (en) 2001-10-31 2004-03-16 Conagra Foods Inc. Low glycemic index bread
WO2003094849A2 (en) * 2002-05-10 2003-11-20 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
WO2006050270A2 (en) 2004-11-02 2006-05-11 The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services Compositions and methods for treating hyperproliferative disorders
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8110196B2 (en) 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20100111973A1 (en) 2006-09-22 2010-05-06 Glenn Dranoff Methods for treating mica-related disorders
WO2011046842A1 (en) 2009-10-12 2011-04-21 The Regents Of The University Of California Targeted nanoclusters and methods of their use
WO2011074573A1 (ja) 2009-12-18 2011-06-23 花王株式会社 メソポーラスシリカ粒子の製造方法
JP5603063B2 (ja) 2009-12-21 2014-10-08 花王株式会社 複合シリカ粒子の製造方法
RU2489169C2 (ru) * 2010-10-12 2013-08-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Способ лечения онкологических заболеваний
AU2012311238A1 (en) * 2011-09-23 2014-04-17 University Of Oslo Vaccibodies targeted to cross-presenting dendritic cells
PT2760471T (pt) 2011-09-30 2017-03-22 Dana Farber Cancer Inst Inc Péptidos terapêuticos
RU2656183C2 (ru) 2012-02-07 2018-05-31 Иннейт Фарма Связывающие mica агенты
EP3662896B1 (en) 2012-04-16 2024-02-28 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
EP3666886A1 (en) 2013-03-15 2020-06-17 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP6518199B6 (ja) 2013-03-15 2019-06-12 ノヴェロジックス・バイオテクノロジー，インコーポレーテッド Ｍｉｃａおよびｍｉｃｂタンパク質に対する抗体
CN106456728A (zh) * 2014-03-14 2017-02-22 达纳－法伯癌症研究所公司 恢复对抗癌症的nkg2d通路功能的疫苗组合物和方法

Also Published As

Publication number Publication date
US20250064863A1 (en) 2025-02-27
IL259490A (en) 2018-07-31
US20180353581A1 (en) 2018-12-13
CL2023003217A1 (es) 2024-06-28
CR20180350A (es) 2018-10-02
MX2022010194A (es) 2022-09-19
NZ742663A (en) 2023-02-24
RU2018123307A3 (es) 2020-04-20
PH12018501170A1 (en) 2019-01-21
EP3383426A1 (en) 2018-10-10
AU2016362597A1 (en) 2018-06-07
CR20230116A (es) 2023-05-05
JP2022130623A (ja) 2022-09-06
CA3005910A1 (en) 2017-06-08
US20210299186A1 (en) 2021-09-30
CU20180050A7 (es) 2018-11-06
BR112018010705A8 (pt) 2019-02-26
US10993971B2 (en) 2021-05-04
RU2018123307A (ru) 2020-01-13
TN2018000187A1 (en) 2019-10-04
CL2021001256A1 (es) 2021-12-31
BR112018010705A2 (pt) 2018-11-21
CN108770343A (zh) 2018-11-06
CU24609B1 (es) 2022-06-06
JP7564842B2 (ja) 2024-10-09
JP7099956B2 (ja) 2022-07-12
JP2018536002A (ja) 2018-12-06
CL2018001470A1 (es) 2018-12-21
JP2024177207A (ja) 2024-12-19
KR20180088458A (ko) 2018-08-03
RU2747296C2 (ru) 2021-05-04
AU2016362597C1 (en) 2022-05-26
MX2018006785A (es) 2018-11-09
AU2016362597B2 (en) 2022-02-17
MY199248A (en) 2023-10-23
PE20181158A1 (es) 2018-07-19
AU2022201940A1 (en) 2022-04-14
RU2021109510A (ru) 2021-04-16
ZA202204223B (en) 2023-12-20
WO2017096374A1 (en) 2017-06-08
CO2018006642A2 (es) 2018-07-10
CU20210061A7 (es) 2022-02-04
SG11201804597TA (en) 2018-06-28
EA201891287A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
CL2023003217A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CL2018001358A1 (es) Composiciones que comprenden cepas bacterianas
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
PE20180673A1 (es) Tratamiento contra el cancer por manipulacion de la microflora comensal
MD4733B1 (ro) Anticorpi anti-TIGIT
MX360041B (es) Composiciones y metodos para el cuidado personal.
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
EA201692552A1 (ru) МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
BR112018070255A2 (pt) reprogramação cardíaca direta melhorada.
BR112016019389A8 (pt) Vacina, e, peptídeo
PH12016501838A1 (en) Compounds and their methods of use
BR112019004102A2 (pt) imunoterapia para poliomavírus
AU355238S (en) Dental appliance
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.